Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance

Core Insights - Sanofi reported a Q3 sales growth of 15.7% at constant exchange rates (CER), with business EPS of €2.86, reflecting strong performance across its portfolio [1][3] - The company confirmed a full-year 2024 sales target of approximately €13 billion for Dupixent, which saw a 23.8% increase in sales to €3,476 million [1][3] - Sanofi upgraded its 2024 business EPS guidance to a growth of at least a low single-digit percentage at CER, excluding Opella [2][3] Financial Performance - Q3 IFRS net sales were reported at €13,438 million, a 12.3% increase, with a 15.7% change at CER [4] - Business operating income for Q3 was €4,607 million, up 14.4%, while business net income reached €3,585 million, reflecting a 12.2% increase [5] - Free cash flow for Q3 was €3,327 million, showing a significant increase of 79.5% [5] Product and Pipeline Developments - Sales from new pharmaceutical launches increased by 67.1% to €727 million, driven by products like ALTUVIIIO, Nexviazyme, and Rezurock [1] - Vaccine sales rose by 25.5%, supported by the timing of flu sales and increased capacity for Beyfortus [1] - Sanofi achieved four regulatory approvals and four positive phase 3 data readouts in Q3, including for Dupixent in COPD and other indications [1][3] Strategic Moves - Sanofi entered exclusive negotiations with CD&R to transfer a controlling stake in Opella, allowing the company to focus on innovative medicines and vaccines [1][3]